New Covid-19 Variant B.1.1.529 (Omicron) Emerges in Africa
Gilead and the NIH Appear to be Holding Back Data on LNC Remdesivir
Merck’s Covid Pill Reduces Hospitalization by About 50%
Early Use of Remdesivir Reduces Hospitalization by 87%
The Market Potential of Oral Remdesivir
Is Gilead Holding Back Data on Inhaled Remdesivir?
Gilead Set to Soar as South African COVID-19 Strain Might Resist Vaccines